Delivery Order SPE2DB22D2206-SPE2DB25FJS90
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,413.60 on August 25, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract is classified as a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this order. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a $2,232.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 200 mg on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery to support federal medical procurement needs, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,830.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract, which is set to complete by August 20, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on August 22, 2025, for the supply of Xcopri 200 mg tablets in quantities of 30 tablets. The contract, valued at $1,879.85 with a firm fixed price structure, represents a competitive award with no set-aside designation. Performance will be executed from the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 25, 2025. This delivery...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Xcopri 100 mg tablets (30-count units) with a ceiling value of $2,947.40. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The contract has an ultimate completion date of July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $4,330.58 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Xcopri 50 mg tablets (30-count). This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 31, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. AmerisourceBergen Drug Corp, a major pharmaceutical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 5, 2025, by the Defense Logistics Agency for the supply of Xcopri 100 mg tablets (30-count package) with a ceiling value of $4,846.14. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,221.54 to AmerisourceBergen Drug Corp for the supply of Xcopri 100 mg tablets (30-count packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,396.12 to AmerisourceBergen Drug Corp for the supply of Xcopri 50 mg tablets (30-count units). This competitively awarded, firm fixed price delivery order was issued on August 18, 2025, with an ultimate completion date of August 19, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a discrete transaction under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,768.44 for XCOPRI 150 mg tablets (30-count units) with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the company's corporate office in Conshohocken, Pennsylvania. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJS90Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,080.32 on September 2, 2025, for the supply of Xcopri 200 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract was issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal vendor for military and veteran healthcare systems through the DLA Medical Supply Chain. The company maintains an extensive portfolio of federal contract awards covering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for Xcopri, a neurological treatment medication, represents one of numerous small-value transactions the company fulfills through its prime vendor relationship, demonstrating its capability to meet diverse federal medical procurement requirements through competitive contracting.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 9/2/25 |